Galena Biopharma Fund Predictions

Buy GALE

*Your capital is at risk

$0.260

+0 (+0%)

At Close: Apr 17, 2018

Currently predicting for Mon, 8 Jun 2026

GALE Prediction Chart

GALE Predictions History

Latest community submissions for GALE.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Oct 6, 2017	$0.393 -3.89%	$0.410	V	96.10%	0
JuanC Villegas Pro	Jul 5, 2017	$0.594 +2.24%	$0.580	X	97.80%	0
JS Pro	Jul 5, 2017	$0.598 +2.93%	$0.580	X	97.10%	0
bbullish2 Merchant @bbullish2.7792	Jul 5, 2017	$0.581 +0.00%	$0.580	V	100.00%	10
alex @alex.9092	Jul 5, 2017	$0.541 -6.88%	$0.580	V	93.10%	0
JS Pro	Feb 15, 2017	$0.80 +4.43%	$0.770	V	95.60%	0
turki @turki.1507	Feb 15, 2017	$0.730 -4.95%	$0.770	X	95.10%	0
Drafrago	Feb 15, 2017	$0.730 -4.95%	$0.770	X	95.10%	0
Ron.Boutwell.1883	Feb 15, 2017	$0.760 -1.04%	$0.770	X	99.00%	1
JS Pro	Dec 15, 2016	$1.92 -5.88%	$2.04	X	94.10%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for GALE with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT GALENA BIOPHARMA

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs. The companys lead product candidate, NeuVax (nelipepimut-S), is in Phase III clinical trials for the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combi...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
RUN $12.83	4.09%	May 06
GLBE $31.61	1.65%	May 05
SAP $172.39	7.18%	May 05
FIZZ $34.11	7.04%	May 01
ADBE $243.57	3.23%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by